

// DESIGNER CIRCULAR RNA AS PROTEIN SPONGE FOR CANCER THERAPY


Ref-Nr: TA-TM1070

HINTERGRUND

The new circular RNA is very stable, it can easily be transfected into cells. It is used to sponge and thereby inhibit selectively hnRNP L.

LÖSUNG

A new artificial circular RNA with an unusual ribonucleotide sequence was designed to bind and inhibit intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L). HnRNP L plays an essential role in the development of pancreatic and other cancer types.



© Prof. Dr. Albrecht Bindereif, Justus-Liebig-Universität Gießen

Metabolically stable protein-sponge-forming circular RNA

VORTEILE

- Circular RNA is much more stable than the corresponding linear RNA.
- Circular RNA can be designed to sponge RNA-binding proteins, thereby



Gesellschaft für
Technologietransfer mbH

TransMIT Gesellschaft für
Technologietransfer mbH

Anouschka Ulherr
0641 946434
anouschka.ulherr@transmit.de

ENTWICKLUNGSSTAND

Leitstruktur

CATEGORIES

//Life Sciences //Medizin und
Pharma //Therapie und Wirkstoffe

inhibiting the metabolic function of such proteins.

- Circular RNA can easily be introduced into cells and has no adverse side effects.
 - A circular RNA was designed to bind hnRNP L with high specificity and affinity, inactivating this protein and thus opening up new therapy options for pancreatic and other cancer types, where hnRNP L is deregulated.
-

ANWENDUNGSBEREICHE

The new circular RNA is useful in pancreatic and oral squamous cell cancer therapy, when hnRNP L is overexpressed, based on binding and inhibiting intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L).

SERVICE

On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.
